Prosecution Insights
Prosecution Insights
18 pending office actions • 7 clients • 17 examiners • 13 art units • 0 of 18 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (11%) |
| §103 only | 4 (22%) |
| Double-patenting only | 1 (6%) |
| Double-patenting + other | 2 (11%) |
| Multi-statute (no §101) | 9 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CABRAL, ROBERT S | 2 | 62.6% | +32.4% |
| BUI, LUAN KIM | 1 | 69.1% | +28.3% |
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.0% |
| SAMALA, JAGADISHWAR RAO | 1 | 67.9% | +55.5% |
| BERA, HENA RAKESHKUMAR | 1 | — | — |
| GROOMS, NOA WILLIAM FRAN | 1 | 100.0% | +0.0% |
| VANNI, GEORGE STEVEN | 1 | 67.0% | +24.4% |
| KANAAN, TONY P | 1 | 29.3% | +28.6% |
| WEINER, LAURA S | 1 | 85.2% | +14.3% |
| SCHLIENTZ, LEAH H | 1 | 41.9% | +38.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17494690 | MODULATING ISCHEMIC INJURY | CLARKE, TRENT R | 141d overdue |
| 18883446 | RESILIENT EXPANDABLE STERILIZABLE PACKAGING FOR INDIVIDUAL ITEMS | BUI, LUAN KIM | 13d |
| 18374875 | METHOD FOR IDENTIFYING AND INITIATING REVERSIBLE SUBROGATION CLAIMS | KANAAN, TONY P | 14d |
| 16754400 | METHODS FOR CANCER TREATMENT USING A RADIOLABELED ANTI-CD45 IMMUNOGLOBULIN AND ADOPTIVE CELL THERAPIES | BUTTICE, AUDREY L | 33d |
| 18514319 | RELATIONAL BIOMARKERS THAT DISTINGUISH DISEASES AND DISORDERS FROM CONTROLS AND USES THEREOF TO PREDICT PATHOPHYSIOLOGICAL OUTCOMES | VANNI, GEORGE STEVEN | 84d |
| 18684103 | RADIOIMMUNOCONJUGATES TARGETING CALRETICULIN FOR USE IN THE TREATMENT OF CANCER | SAMALA, JAGADISHWAR RAO | — |
| 18441844 | REACTIVE CONDENSATION PARTICLE COUNTER FOR THE DETECTION OF TRACE ATMOSPHERIC GASES | BERA, HENA RAKESHKUMAR | — |
| 18292413 | MAGNETIC COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | GROOMS, NOA WILLIAM FRAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18883446 | RESILIENT EXPANDABLE STERILIZABLE PACKAGING FOR INDIVIDUAL ITEMS | BUI, LUAN KIM | 13d |
| 18374875 | METHOD FOR IDENTIFYING AND INITIATING REVERSIBLE SUBROGATION CLAIMS | KANAAN, TONY P | 14d |
| 18514319 | RELATIONAL BIOMARKERS THAT DISTINGUISH DISEASES AND DISORDERS FROM CONTROLS AND USES THEREOF TO PREDICT PATHOPHYSIOLOGICAL OUTCOMES | VANNI, GEORGE STEVEN | 84d |
| 18806385 | METHODS FOR TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES | CABRAL, ROBERT S | — |
| 18684103 | RADIOIMMUNOCONJUGATES TARGETING CALRETICULIN FOR USE IN THE TREATMENT OF CANCER | SAMALA, JAGADISHWAR RAO | — |
| 18369331 | ELECTRODE SURFACE ENGINEERING IN LITHIUM ION BATTERIES | WEINER, LAURA S | — |
| 18036723 | METHODS FOR TREATING CANCER USING COMBINATIONS OF EPIGENETIC THERAPIES AND RADIOCONJUGATE TARGETING AGENTS | SCHLIENTZ, LEAH H | — |
| 17725544 | COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER | CABRAL, ROBERT S | — |
| Client (Assignee) | Pending OAs |
|---|---|
| ACTINIUM PHARMACEUTICALS, INC. | 9 |
| NOVEOME BIOTHERAPEUTICS, INC. | 3 |
| Carnegie Mellon University | 2 |
| Roesler IP GmbH | 1 |
| Horizon Technology | 1 |
| Signature Diagnostics Inc. | 1 |
| Second Look, Inc. | 1 |
| Art Unit | Apps |
|---|---|
| 1618 | 3 |
| 3736 | 1 |
| 1625 | 1 |
| 2877 | 1 |
| 1686 | 1 |
| 3696 | 1 |
| 1723 | 1 |
| 1614 | 1 |
| 1651 | 1 |
| 1674 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18883446 | RESILIENT EXPANDABLE STERILIZABLE PACKAGING FOR INDIVIDUAL ITEMS | Roesler Ip GmbH | BUI, LUAN KIM | 3736 | §102§103§112 | Non-Final OA | 13d | Pending | Sep 12, 2024 |
| 18806385 | METHODS FOR TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES | Actinium Pharmaceuticals, Inc. | CABRAL, ROBERT S | DP | Non-Final OA | — | Pending | Aug 15, 2024 | |
| 18610927 | BIFUNCTIONAL CHELATORS AND CONJUGATES | Actinium Pharmaceuticals, Inc. | SEAMAN, D MARGARET M | 1625 | §102§112DP | Non-Final OA | — | Pending | Mar 20, 2024 |
| 18684103 | RADIOIMMUNOCONJUGATES TARGETING CALRETICULIN FOR USE IN THE TREATMENT OF CANCER | Actinium Pharmaceuticals, Inc. | SAMALA, JAGADISHWAR RAO | §102§103 | Non-Final OA | — | Pending | Feb 15, 2024 | |
| 18441844 | REACTIVE CONDENSATION PARTICLE COUNTER FOR THE DETECTION OF TRACE ATMOSPHERIC GASES | Carnegie Mellon University | BERA, HENA RAKESHKUMAR | 2877 | §102§103§112 | Non-Final OA | — | Pending | Feb 14, 2024 |
| 18292413 | MAGNETIC COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | Horizon Technology | GROOMS, NOA WILLIAM FRAN | §103§112 | Non-Final OA | — | Pending | Jan 26, 2024 | |
| 18514319 | RELATIONAL BIOMARKERS THAT DISTINGUISH DISEASES AND DISORDERS FROM CONTROLS AND USES THEREOF TO PREDICT PATHOPHYSIOLOGICAL OUTCOMES | Signature Diagnostics Inc. | VANNI, GEORGE STEVEN | 1686 | §101§112 | Non-Final OA | 84d | Pending | Nov 20, 2023 |
| 18374875 | METHOD FOR IDENTIFYING AND INITIATING REVERSIBLE SUBROGATION CLAIMS | Second Look, Inc. | KANAAN, TONY P | 3696 | §101§103 | Non-Final OA | 14d | Pending | Sep 29, 2023 |
| 18369331 | ELECTRODE SURFACE ENGINEERING IN LITHIUM ION BATTERIES | Carnegie Mellon University | WEINER, LAURA S | 1723 | §102§103§112 | Non-Final OA | — | Pending | Sep 18, 2023 |
| 18036723 | METHODS FOR TREATING CANCER USING COMBINATIONS OF EPIGENETIC THERAPIES AND RADIOCONJUGATE TARGETING AGENTS | Actinium Pharmaceuticals, Inc. | SCHLIENTZ, LEAH H | 1618 | §102§103 | Non-Final OA | — | Pending | May 12, 2023 |
| 18025849 | TROPHOBLAST GLYCOPROTEIN RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS | Actinium Pharmaceuticals, Inc. | CRAIG, KAILA ANGELIQUE | 1618 | §103 | Non-Final OA | 39d | Pending | Mar 10, 2023 |
| 17725544 | COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER | Actinium Pharmaceuticals, Inc. | CABRAL, ROBERT S | 1614 | §103§112DP | Non-Final OA | — | Pending | Apr 20, 2022 |
| 17494690 | MODULATING ISCHEMIC INJURY | Noveome Biotherapeutics, Inc. | CLARKE, TRENT R | 1651 | §102§103§112Other | Final Rejection | 141d overdue | Pending | Oct 05, 2021 |
| 17293663 | COMBINATION OF RADIOIMMUNOTHERAPY AND IMMUNE CHECKPOINT THERAPY IN THE TREATMENT OF CANCER | Actinium Pharmaceuticals, Inc. | VU, JAKE MINH | 1618 | §102§103§112Other | Non-Final OA | — | Pending | May 13, 2021 |
| 17197580 | Use of ST266 to Treat Severe Systemic Inflammation and Post-Acute COVID-19 Syndrome | Noveome Biotherapeutics, Inc. | FORD, VANESSA L | 1674 | §103 | Final Rejection | 6d | Pending | Mar 10, 2021 |
| 16954105 | COMBINATION IMMUNOTHERAPY AND CHEMOTHERAPY FOR THE TREATMENT OF A HEMATOLOGICAL MALIGNANCY | Actinium Pharmaceuticals, Inc. | WELLS, LAUREN QUINLAN | 1622 | §103 | Non-Final OA | 30d overdue | Pending | Jun 15, 2020 |
| 16754400 | METHODS FOR CANCER TREATMENT USING A RADIOLABELED ANTI-CD45 IMMUNOGLOBULIN AND ADOPTIVE CELL THERAPIES | Actinium Pharmaceuticals, Inc. | BUTTICE, AUDREY L | 1647 | §103§112 | Final Rejection | 33d | Pending | Apr 08, 2020 |
| 16690197 | Novel methods for delivering therapeutics agents to the eye via the nasal passages | Noveome Biotherapeutics, Inc. | MOSS, NATALIE M | 1653 | §103Other | Non-Final OA | 6d | Pending | Nov 21, 2019 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial